Compare Indoco Remedies with Motilal Oswal - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs MOTILAL OSWAL - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

MOTILAL OSWAL 
   Change

Motilal Oswal Financial Services (MOFSL) derives a significant portion of its revenues from equity broking (69% in FY12) for both retail and institutional clients. Accordingly, its revenues and profits are dependent on favourable capital market condi... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES MOTILAL OSWAL INDOCO REMEDIES/
MOTILAL OSWAL
 
P/E (TTM) x 51.1 30.6 167.1% View Chart
P/BV x 2.0 4.3 46.6% View Chart
Dividend Yield % 0.7 0.7 101.6%  

Financials

 INDOCO REMEDIES   MOTILAL OSWAL
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
MOTILAL OSWAL
Mar-18
INDOCO REMEDIES/
MOTILAL OSWAL
5-Yr Chart
Click to enlarge
High Rs3171,585 20.0%   
Low Rs178734 24.3%   
Sales per share (Unadj.) Rs113.1189.4 59.7%  
Earnings per share (Unadj.) Rs4.538.7 11.5%  
Cash flow per share (Unadj.) Rs11.841.3 28.6%  
Dividends per share (Unadj.) Rs1.004.50 22.2%  
Dividend yield (eoy) %0.40.4 104.0%  
Book value per share (Unadj.) Rs73.2156.4 46.8%  
Shares outstanding (eoy) m92.15145.08 63.5%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x2.26.1 35.8%   
Avg P/E ratio x55.530.0 185.1%  
P/CF ratio (eoy) x21.028.1 74.7%  
Price / Book Value ratio x3.47.4 45.6%  
Dividend payout %22.411.6 192.6%   
Avg Mkt Cap Rs m22,830168,228 13.6%   
No. of employees `0005.5NA 34,093.8%   
Total wages/salary Rs m2,2095,001 44.2%   
Avg. sales/employee Rs Th1,910.11,717,468.8 0.1%   
Avg. wages/employee Rs Th405.0312,581.3 0.1%   
Avg. net profit/employee Rs Th75.5350,962.5 0.0%   
INCOME DATA
Net Sales Rs m10,41927,480 37.9%  
Other income Rs m47217 21.6%   
Total revenues Rs m10,46627,697 37.8%   
Gross profit Rs m1,34912,779 10.6%  
Depreciation Rs m677375 180.6%   
Interest Rs m2354,956 4.7%   
Profit before tax Rs m4847,666 6.3%   
Minority Interest Rs m0-98 0.0%   
Prior Period Items Rs m091 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m722,043 3.5%   
Profit after tax Rs m4125,615 7.3%  
Gross profit margin %12.946.5 27.8%  
Effective tax rate %15.026.7 56.1%   
Net profit margin %4.020.4 19.3%  
BALANCE SHEET DATA
Current assets Rs m5,37329,019 18.5%   
Current liabilities Rs m4,15741,835 9.9%   
Net working cap to sales %11.7-46.6 -25.0%  
Current ratio x1.30.7 186.3%  
Inventory Days Days680 188,892.1%  
Debtors Days Days73139 52.5%  
Net fixed assets Rs m6,2443,113 200.6%   
Share capital Rs m184145 127.0%   
"Free" reserves Rs m6,56622,540 29.1%   
Net worth Rs m6,75022,685 29.8%   
Long term debt Rs m1,23332,329 3.8%   
Total assets Rs m12,36398,645 12.5%  
Interest coverage x3.12.5 120.1%   
Debt to equity ratio x0.21.4 12.8%  
Sales to assets ratio x0.80.3 302.6%   
Return on assets %5.210.7 48.8%  
Return on equity %6.124.8 24.6%  
Return on capital %9.022.9 39.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,1430-   
Net fx Rs m2,6190-   
CASH FLOW
From Operations Rs m1,2271,118 109.8%  
From Investments Rs m-1,360-1,907 71.3%  
From Financial Activity Rs m-388715 -54.2%  
Net Cashflow Rs m-521-91 574.0%  

Share Holding

Indian Promoters % 59.2 74.1 79.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 7.5 166.7%  
FIIs % 6.0 5.3 113.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 13.1 171.0%  
Shareholders   12,805 11,283 113.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   NALWA SONS INV  GREENPLY INDUSTRIES  TATA INVESTMENT  EDELWEISS FINANCIAL  S.P. APPARELS  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

MOTILAL OSWAL Announces Quarterly Results (4QFY19); Net Profit Up 0.3% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MOTILAL OSWAL has posted a net profit of Rs 1 bn (up 0.3% YoY). Sales on the other hand came in at Rs 7 bn (down 12.7% YoY). Read on for a complete analysis of MOTILAL OSWAL's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Nov 11, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS